ACHN News and Press, Achison Inc Cl A From 10/09/19

Achillion Pharmaceuticals (ACHN) had received Breakthrough Therapy Designation from the FDA for its drug danicopan for the treatment of paroxysmal nocturnal hemoglobinuria ((PNH)). This indication was given because of positive preliminary data, from a phase 2 study, that was released sever...

Achillion Pharmaceuticals ( ACHN ) made a remarkable recovery in 2019. The stock started the year below $2 per share and traded up to $5 per share last month. I started following the stock this year and wrote two articles on it and my take was that I am interested in the story but neutral on...

BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President ...

Shares of BioCryst Pharmaceuticals ( BCRX ) are stuck around $3 per share ever since the stock plunged after reporting phase 3 results of BCX7353 in hereditary angioedema (‘HAE’) in May. The subpar phase 3 results (relative to an available competing therapy) and the company...

ACHN stock is leading in the biotech sector after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that the FDA has granted Breakthrough Therapy Designation (BTD) for danicopan (ACH-4471). Investors Cheer the News When a pharmaceutical company releases highly encouraging informat...

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) were jumping 7.5% higher as of 10:46 a.m. EDT on Wednesday after rising as much as 18% earlier in the day. The nice gain came after the biotech announced that the Food and Drug Administration granted a Breakthrough Therapy designation for da...

PhaseBio Pharmaceuticals (NASDAQ: PHAS )  +21%  on end of PB2452 trial . More news on: PhaseBio Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Philip Morris International Inc., Stocks on the move, Read more ...

Achillion Pharmaceuticals (NASDAQ: ACHN ) is up  14%  premarket in response to its announcement that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with paroxysmal nocturnal hem...

– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 – – Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage b...

BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President a...